The Europe Body Fluid Collection And Diagnostics Market would witness market growth of 6.5% CAGR during the forecast period (2022-2028).
Human body fluids are considered as the most adequate source for the clinical makers regarding the diagnosis of diseases. The benefit of body fluid testing is that they are less invasive, affordable, and can help in quick diagnostics.
Apart from this, altered protein expression profile in body fluid shows the conversion of the phycological states and cellular network of the disease or tissues. Therefore, the diagnostics through the body fluid has emerged as an outstanding approach to identify and discover the biomarkers or expose pathological mechanisms for human disease.
The examination of the human body fluid is fundamentally challenging because of its unique characteristics like protein complexity and the large active variety of protein collection, because of the extraordinary enhancement in the process of sample preparation, proteomics technology, and quantitation, with the increased sensitivity and robust experimental design it is now possible to examine body fluid more effectively.
In the United Kingdom people under age of 40 in the UK are being diagnosed with type 2 diabetes, at a faster rate. Also, the obese and overweight citizens in the nation are increasing rapidly. Due to this rising number of obese citizens, there are high chances of the people getting type 2 diabetes, especially among those aged 18 to 39. Almost 8% of the citizen with diabetes have type 1 diabetes and almost 90% of the citizen with diabetes have type 2 diabetes. This increasing number of diabetic patients will rise the growth opportunities for the body fluid collection and diagnostics market.
The Germany market dominated the Europe Body Fluid Collection And Diagnostics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $2,676.3 million by 2028. The UK market is anticipated to grow at a CAGR of 5.6% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 7.2% during (2022 - 2028).
Based on Product, the market is segmented into Kits & Consumables, Instruments and Tests/Services. Based on Technology, the market is segmented into Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Fluorescence in situ hybridization (FISH) and Others. Based on Sample Type, the market is segmented into Blood, Urine, Saliva and Cerebrospinal Fluid. Based on Application, the market is segmented into Diagnostics & Monitoring, Therapeutic Decision Making and Prognostics & Screening. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Body Fluid Collection And Diagnostics Market will Hit $42.2 Billion by 2028, at a CAGR of 6.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Qiagen N.V., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Laboratory Corporation of America Holdings, Biocept, Inc., MDxHealth SA, and Guardant Health, Inc.
By Product
By Technology
By Sample Type
By Application
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
